Florence Tubach
Overview
Explore the profile of Florence Tubach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
245
Citations
4943
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ricci L, Fery C, Tubach F, Agrinier N, Gagneux-Brunon A
Vaccine
. 2025 Mar;
54:127005.
PMID: 40088510
Background: ESPERES, a prospective e-cohort study is designed to assess attitudes and perceptions of the COVID-19 pandemic among French health care workers. Objectives: We aimed to document (i) their confidence...
2.
Januel E, Corvol J, Remy P, Meissner W, Thiriez C, Lanore A, et al.
Fundam Clin Pharmacol
. 2025 Mar;
39(2):e70002.
PMID: 40062736
Context: After observing increased sudden death risk associated with domperidone use, the European Medicines Agency (EMA) imposed usage restrictions in 2014, limiting age (≤60 years), daily dose (≤30 mg/day), and...
3.
Gavaud A, Holub M, Asquier-Khati A, Faure K, Leautez-Nainville S, Le Moal G, et al.
Lancet Infect Dis
. 2025 Feb;
PMID: 39986287
Background: An epidemic of Mycoplasma pneumoniae infection has been observed in France since September, 2023. We aimed to describe the characteristics of adults hospitalised for M pneumoniae infection and identify...
4.
Plomp L, Chassepot H, Psimaras D, Maisonobe T, Mensi E, Leonard-Louis S, et al.
Lancet Reg Health Eur
. 2025 Feb;
50:101192.
PMID: 39896961
Background: Immune checkpoint inhibitors (ICIs) may induce overlapping myositis/myasthenia gravis (MG) features, sparking current debate about pathophysiology and management of this emerging disease entity. We aimed to clarify whether ICI-induced...
5.
Salem J, Ederhy S, Belin L, Zahr N, Tubach F, Procureur A, et al.
Arch Cardiovasc Dis
. 2025 Jan;
118(2):106-115.
PMID: 39743436
Background: Immune checkpoint inhibitor (ICI)-induced myocarditis is a life-threatening adverse drug reaction. Abatacept (a CTLA-4-immunoglobulin fusion protein) has been proposed as a compassionate-use treatment for ICI myocarditis (in combination with...
6.
Latour M, Vauzelle C, Elefant E, Tubach F, Padberg S, Martin B, et al.
Eur J Epidemiol
. 2024 Dec;
39(12):1325-1340.
PMID: 39658659
The risks related to fluconazole use during the first trimester of pregnancy (T1) remain controversial. The aims of this systematic review and meta-analysis were to assess the association between oral...
7.
Teboul A, Allenbach Y, Tubach F, Belin L, Cassius C, Demortier J, et al.
Rheumatology (Oxford)
. 2024 Nov;
PMID: 39589730
Objectives: To investigate factors associated with dermatomyositis (DM) complete clinical response and overall survival with a focus on the use of immunosuppressive therapies in patients with cancer-associated DM. Methods: We...
8.
Simon-Tillaux N, Martin G, Hajage D, Scheifer C, Beydon M, Dechartres A, et al.
BMJ Open
. 2024 Nov;
14(11):e086595.
PMID: 39532374
Objectives: Target trial emulation is an approach that is increasingly used to improve transparency in observational studies and help mitigate biases. For studies declaring that they emulated a target trial,...
9.
Cancella de Abreu M, Ropers J, Oueidat N, Pieroni L, Frere C, Fontenay M, et al.
Eur J Emerg Med
. 2024 Oct;
31(6):429-437.
PMID: 39480645
Background: During a pandemic like COVID-19, hospital resources are constrained and accurate severity triage of the patients is required. Objective: The objective of this study is to estimate the predictive...
10.
Calonge Q, Le Gac F, Chavez M, Degremont A, Quantin C, Tubach F, et al.
J Neurol
. 2024 Aug;
271(10):6761-6772.
PMID: 39177750
Background: Status epilepticus (SE) imposes a significant burden in terms of in-hospital mortality and costs, but the relationship between SE causes, patient comorbidities, mortality, and cost remains insufficiently understood. We...